Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism?

Lancet. 1994 Aug 6;344(8919):371-3. doi: 10.1016/s0140-6736(94)91402-8.

Abstract

Endothelial dysfunction in heart failure could impair nitric oxide production and lead to increased vascular resistance. If endogenous production of nitric oxide is reduced, NG-monomethyl-L-arginine (L-NMMA), an inhibitor of such production, should have a diminished vasoconstrictor effect. We administered L-NMMA to 12 patients being investigated for heart failure. L-NMMA increased median pulmonary and systemic vascular resistances by 61 (range -3 to 240) and 430 (63 to 1609) dynes s cm-5, respectively (p < 0.03 and p < 0.005). Arterial pressures also increased. Median cardiac output fell by 0.6 (0 to -2.3) L per min (p < 0.005). These data suggest that vascular nitric oxide may be another example of a failed counter-regulatory vasodilator system in heart failure.

MeSH terms

  • Aged
  • Arginine / analogs & derivatives*
  • Arginine / pharmacology
  • Arginine / therapeutic use
  • Cardiac Output, Low / drug therapy*
  • Cardiac Output, Low / metabolism
  • Female
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Heart Function Tests
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / antagonists & inhibitors*
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / pharmacology
  • Nitric Oxide / physiology
  • Nitric Oxide / therapeutic use*
  • Vasodilation / drug effects
  • Vasodilation / physiology
  • omega-N-Methylarginine

Substances

  • omega-N-Methylarginine
  • Nitric Oxide
  • Arginine